{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:44:14Z","timestamp":1791290654856,"version":"4.3.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Imperial ECMC"},{"name":"Leicester ECMC"},{"name":"Cancer Research UK Leicester Centre"},{"name":"Cancer Research UK Clinical and Translational Research Committee","award":["C14315\/A13462X"],"award-info":[{"award-number":["C14315\/A13462X"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Activating mutations in the estrogen receptor 1 (ESR1) gene are acquired on treatment and can drive resistance to endocrine therapy. Because of the spatial and temporal limitations of needle core biopsies, our goal was to develop a highly sensitive, less invasive method of detecting activating ESR1 mutations via circulating cell-free DNA (cfDNA) and tumor cells as a \u201cliquid biopsy.\u201d<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We developed a targeted 23-amplicon next-generation sequencing (NGS) panel for detection of hot-spot mutations in ESR1, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA), tumor protein p53 (TP53), fibroblast growth factor receptor 1 (FGFR1), and fibroblast growth factor receptor 2 (FGFR2) in 48 patients with estrogen receptor-\u03b1\u2013positive metastatic breast cancer who were receiving systemic therapy. Selected mutations were validated using droplet digital PCR (ddPCR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Nine baseline cfDNA samples had an ESR1 mutation. NGS detected 3 activating mutations in ESR1, and 3 hot-spot mutations in PIK3CA, and 3 in TP53 in baseline cfDNA, and the ESR1 p.D538G mutation in 1 matched circulating tumor cell sample. ddPCR analysis was more sensitive than NGS and identified 6 additional baseline cfDNA samples with the ESR1 p.D538G mutation at a frequency of &amp;lt;1%. In serial blood samples from 11 patients, 4 showed changes in cfDNA, 2 with emergence of a mutation in ESR1. We also detected a low frequency ESR1 mutation (1.3%) in cfDNA of 1 primary patient who was thought to have metastatic disease but was clear by scans.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Early identification of ESR1 mutations by liquid biopsy might allow for cessation of ineffective endocrine therapies and switching to other treatments, without the need for tissue biopsy and before the emergence of metastatic disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1373\/clinchem.2015.238717","type":"journal-article","created":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T23:15:43Z","timestamp":1431731743000},"page":"974-982","source":"Crossref","is-referenced-by-count":151,"title":["Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor\u2013Positive Metastatic Breast Cancer"],"prefix":"10.1093","volume":"61","author":[{"given":"David S","family":"Guttery","sequence":"first","affiliation":[{"name":"Department of Cancer Studies and Cancer Research UK Leicester Centre, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Page","sequence":"first","affiliation":[{"name":"Department of Cancer Studies and Cancer Research UK Leicester Centre, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Hills","sequence":"first","affiliation":[{"name":"Imperial College, Department of Surgery and Cancer, Charing Cross Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Woodley","sequence":"first","affiliation":[{"name":"Experimental Cancer Medicine Centre Network, Imperial College, Charing Cross Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie D","family":"Marchese","sequence":"first","affiliation":[{"name":"Imperial College, Department of Surgery and Cancer, Charing Cross Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basma","family":"Rghebi","sequence":"first","affiliation":[{"name":"Department of Cancer Studies and Cancer Research UK Leicester Centre, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K","family":"Hastings","sequence":"first","affiliation":[{"name":"Cancer Research UK Leicester Centre, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinli","family":"Luo","sequence":"first","affiliation":[{"name":"Cancer Research UK Leicester Centre, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Howard","family":"Pringle","sequence":"first","affiliation":[{"name":"Department of Cancer Studies and Cancer Research UK Leicester Centre, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Stebbing","sequence":"first","affiliation":[{"name":"Imperial College, Department of Surgery and Cancer, Charing Cross Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Charles","family":"Coombes","sequence":"first","affiliation":[{"name":"Imperial College, Department of Surgery and Cancer, Charing Cross Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simak","family":"Ali","sequence":"first","affiliation":[{"name":"Imperial College, Department of Surgery and Cancer, Charing Cross Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline A","family":"Shaw","sequence":"first","affiliation":[{"name":"Department of Cancer Studies and Cancer Research UK Leicester Centre, University of Leicester, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,7,1]]},"reference":[{"key":"2020022605232310200_B1","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"2020022605232310200_B2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1470-2045(07)70385-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial","volume":"9","author":"Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group","year":"2008","journal-title":"Lancet Oncol"},{"key":"2020022605232310200_B3","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2005","journal-title":"Lancet"},{"key":"2020022605232310200_B4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/187152009788451833","article-title":"Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer","volume":"9","author":"Peng","year":"2009","journal-title":"Anticancer Agents Med Chem"},{"key":"2020022605232310200_B5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2007.03.016","article-title":"Pathways to tamoxifen resistance","volume":"256","author":"Riggins","year":"2007","journal-title":"Cancer Lett"},{"key":"2020022605232310200_B6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/ijms14010108","article-title":"Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance","volume":"14","author":"Garcia-Becerra","year":"2012","journal-title":"Int J Mol Sci"},{"key":"2020022605232310200_B7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev Med"},{"key":"2020022605232310200_B8","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","article-title":"Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor-positive breast cancer","volume":"20","author":"Jeselsohn","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2020022605232310200_B9","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.celrep.2013.08.022","article-title":"Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts","volume":"4","author":"Li","year":"2013","journal-title":"Cell Rep"},{"key":"2020022605232310200_B10","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1158\/0008-5472.CAN-13-1197","article-title":"D538g mutation in estrogen receptor-\u03b1: a novel mechanism for acquired endocrine resistance in breast cancer","volume":"73","author":"Merenbakh-Lamin","year":"2013","journal-title":"Cancer Res"},{"key":"2020022605232310200_B11","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat Genet"},{"key":"2020022605232310200_B12","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer","volume":"45","author":"Toy","year":"2013","journal-title":"Nat Genet"},{"key":"2020022605232310200_B13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"2020022605232310200_B14","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/nm.3600","article-title":"Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer","volume":"20","author":"Hodgkinson","year":"2014","journal-title":"Nat Med"},{"key":"2020022605232310200_B15","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1101\/gr.123497.111","article-title":"Genomic analysis of circulating cell-free DNA infers breast cancer dormancy","volume":"22","author":"Shaw","year":"2012","journal-title":"Genome Res"},{"key":"2020022605232310200_B16","doi-asserted-by":"crossref","first-page":"e103883","DOI":"10.1371\/journal.pone.0103883","article-title":"Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment","volume":"9","author":"Marchetti","year":"2014","journal-title":"PloS One"},{"key":"2020022605232310200_B17","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N Engl J Med"},{"key":"2020022605232310200_B18","doi-asserted-by":"crossref","first-page":"136ra68","DOI":"10.1126\/scitranslmed.3003726","article-title":"Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA","volume":"4","author":"Forshew","year":"2012","journal-title":"Sci Transl Med"},{"key":"2020022605232310200_B19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature12065","article-title":"Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA","volume":"497","author":"Murtaza","year":"2013","journal-title":"Nature"},{"key":"2020022605232310200_B20","doi-asserted-by":"crossref","first-page":"e77963","DOI":"10.1371\/journal.pone.0077963","article-title":"Influence of plasma processing on recovery and analysis of circulating nucleic acids","volume":"8","author":"Page","year":"2013","journal-title":"PloS One"},{"key":"2020022605232310200_B21","doi-asserted-by":"crossref","first-page":"617421","DOI":"10.1155\/2010\/617421","article-title":"Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer","volume":"2010","author":"Miller","year":"2010","journal-title":"J Oncol"},{"key":"2020022605232310200_B22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0002-9440(10)63092-1","article-title":"Whole genome amplification of DNA from laser capture-microdissected tissue for high-throughput single nucleotide polymorphism and short tandem repeat genotyping","volume":"164","author":"Rook","year":"2004","journal-title":"Am J Pathol"},{"key":"2020022605232310200_B23","unstructured":"Thermo Fisher Scientific. Ion AmpliSec designer. https:\/\/www.ampliseq.com (Accessed June 2015)."},{"key":"2020022605232310200_B24","unstructured":"COSMIC. Catalogue of somatic mutations in cancer. http:\/\/cancer.sanger.ac.uk\/cancergenome\/projects\/cosmic\/ (Accessed January 2015)."},{"key":"2020022605232310200_B25","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa0904554","article-title":"Screening for epidermal growth factor receptor mutations in lung cancer","volume":"361","author":"Rosell","year":"2009","journal-title":"N Engl J Med"},{"key":"2020022605232310200_B26","unstructured":"Primer3web. http:\/\/primer3.ut.ee (Accessed January 2015)."},{"key":"2020022605232310200_B27","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal Chem"},{"key":"2020022605232310200_B28","unstructured":"Sigma-Aldrich. OligoArchitectTM online. http:\/\/www.sigmaaldrich.com\/technical-documents\/articles\/biology\/oligoarchitect-online.html (Accessed January 2015)."},{"key":"2020022605232310200_B29","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N Engl J Med"},{"key":"2020022605232310200_B30","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/ng.2831","article-title":"The search for ESR1 mutations in breast cancer","volume":"45","author":"Oesterreich","year":"2013","journal-title":"Nat Genet"},{"key":"2020022605232310200_B31","doi-asserted-by":"crossref","first-page":"11093","DOI":"10.1200\/jco.2014.32.15_suppl.11093","article-title":"Circulating tumor DNA (ctDNA) as a molecular monitoring tool in metastatic breast cancer (MBC) [Abstract]","volume":"32","author":"Austin","year":"2014","journal-title":"J Clin Oncol"},{"key":"2020022605232310200_B32","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","article-title":"Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data","volume":"15","author":"Bidard","year":"2014","journal-title":"Lancet Oncol"},{"key":"2020022605232310200_B33","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1158\/1078-0432.CCR-08-1910","article-title":"Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer","volume":"15","author":"Schwarzenbach","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2020022605232310200_B34","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1373\/clinchem.2014.222331","article-title":"Genomic high-resolution profiling of single CKpos\/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer","volume":"60","author":"Neves","year":"2014","journal-title":"Clin Chem"},{"key":"2020022605232310200_B35","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/bjc.2013.92","article-title":"Semiautomated isolation and molecular characterisation of single or highly purified tumour cells from CellSearch enriched blood samples using dielectrophoretic cell sorting","volume":"108","author":"Peeters","year":"2013","journal-title":"Br J Cancer"},{"key":"2020022605232310200_B36","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.15252\/emmm.201404033","article-title":"Molecular profiling of single circulating tumor cells with diagnostic intention","volume":"6","author":"Polzer","year":"2014","journal-title":"EMBO Mol Med"},{"key":"2020022605232310200_B37","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.bbrc.2003.10.178","article-title":"Both N- and C-terminal transactivation functions of DNA-bound ERalpha are blocked by a novel synthetic estrogen ligand","volume":"312","author":"Yamamoto","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"2020022605232310200_B38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccr.2005.05.014","article-title":"Mutant PIK3CA promotes cell growth and invasion of human cancer cells","volume":"7","author":"Samuels","year":"2005","journal-title":"Cancer Cell"},{"key":"2020022605232310200_B39","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1126\/science.1253533","article-title":"Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility","volume":"345","author":"Yu","year":"2014","journal-title":"Science"},{"key":"2020022605232310200_B40","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N Engl J Med"},{"key":"2020022605232310200_B41","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1056\/NEJMoa032312","article-title":"A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer","volume":"349","author":"Goss","year":"2003","journal-title":"N Engl J Med"},{"key":"2020022605232310200_B42","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nmeth0810-575","article-title":"Mutation Taster evaluates disease-causing potential of sequence alterations","volume":"7","author":"Schwarz","year":"2010","journal-title":"Nat Methods"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/61\/7\/974\/32640383\/clinchem0974.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/61\/7\/974\/32640383\/clinchem0974.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T05:24:26Z","timestamp":1582694666000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/61\/7\/974\/5611499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,1]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7,1]]},"published-print":{"date-parts":[[2015,7,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2015.238717","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,7,1]]},"published":{"date-parts":[[2015,7,1]]}}}